{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:46:57Z","timestamp":1785527217632,"version":"3.56.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00259-026-07941-z","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:15:26Z","timestamp":1780470926000},"page":"5893-5906","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term toxicity of tandem radioligand therapy using [90Y]Y\/[177Lu]Lu-DOTA-TATE in neuroendocrine tumors: a polish multicenter experience with 20-year follow-up"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1943-264X","authenticated-orcid":false,"given":"Maciej","family":"Ko\u0142odziej","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6314-2661","authenticated-orcid":false,"given":"Anna","family":"Zemczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4679-9669","authenticated-orcid":false,"given":"Kacper","family":"Pe\u0142ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0358-0915","authenticated-orcid":false,"given":"Dariusz","family":"Pawlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6756-5415","authenticated-orcid":false,"given":"Katarzyna","family":"J\u00f3\u017awik-Plebanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2357-0634","authenticated-orcid":false,"given":"Grzegorz","family":"Kami\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3755-1722","authenticated-orcid":false,"given":"Beata","family":"Kos-Kud\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7117-9621","authenticated-orcid":false,"given":"Leszek","family":"Kr\u00f3licki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5800-0500","authenticated-orcid":false,"given":"Marek","family":"Saracyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7434-6720","authenticated-orcid":false,"given":"Jolanta","family":"Kunikowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"8","key":"7941_CR1","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1046\/j.1365-2362.1997.1740719.x","volume":"27","author":"P Ja\u00efs","year":"1997","unstructured":"Ja\u00efs P, Terris B, Ruszniewski P et al. Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. Eur J Clin Invest. 1997;27(8):639\u2009\u2013\u200944. https:\/\/doi.org\/10.1046\/j.1365-2362.1997.1740719.x","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"7941_CR2","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1677\/erc.0.0100451","volume":"10","author":"WW de Herder","year":"2003","unstructured":"de Herder WW, Hofland LJ, van der Lely AJ, et al. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2003;10(4):451\u20138. https:\/\/doi.org\/10.1677\/erc.0.0100451","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"7941_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1316158","journal-title":"N Engl J Med"},{"issue":"16","key":"7941_CR4","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1056\/NEJMc1409757","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(16):1556\u20137. https:\/\/doi.org\/10.1056\/NEJMc1409757","journal-title":"N Engl J Med"},{"issue":"4","key":"7941_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1634\/theoncologist.2018-0217","volume":"24","author":"ME Pavel","year":"2019","unstructured":"Pavel ME, Phan AT, Wolin EM, et al. Effect of Lanreotide Depot\/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. Oncologist. 2019;24(4):463\u201374. https:\/\/doi.org\/10.1634\/theoncologist.2018-0217","journal-title":"Oncologist"},{"issue":"3","key":"7941_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1530\/ERC-15-0490","volume":"23","author":"ME Caplin","year":"2016","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer. 2016;23(3):191\u20139. https:\/\/doi.org\/10.1530\/ERC-15-0490","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"7941_CR7","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","volume":"17","author":"J Rubin","year":"1999","unstructured":"Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17(2):600\u20136. https:\/\/doi.org\/10.1200\/JCO.1999.17.2.600","journal-title":"J Clin Oncol"},{"issue":"28","key":"7941_CR8","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller HH, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656\u201363. Epub 2009 Aug 24. PMID: 19704057.","journal-title":"J Clin Oncol"},{"issue":"2","key":"7941_CR9","first-page":"141","volume":"7","author":"H Komek","year":"2019","unstructured":"Komek H, Ansal Balci T, Can C. Efficacy of Galium-68 DOTATATE PET\/CT in the Detection of Metastasis Rate of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Asia Ocean J Nucl Med Biol. 2019;7(2):141\u20138.","journal-title":"Asia Ocean J Nucl Med Biol"},{"issue":"3","key":"7941_CR10","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2967\/jnumed.112.111724","volume":"54","author":"D Wild","year":"2013","unstructured":"Wild D, Bomanji JB, Benkert P, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET\/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54(3):364\u201372. https:\/\/doi.org\/10.2967\/jnumed.112.111724","journal-title":"J Nucl Med"},{"issue":"4","key":"7941_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/0284185113496679","volume":"55","author":"J Yang","year":"2014","unstructured":"Yang J, Kan Y, Ge BH, et al. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol. 2014;55(4):389\u201398. Epub 2013 Aug 8. PMID: 23928010.","journal-title":"Acta Radiol"},{"issue":"6","key":"7941_CR12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3109\/00365521.2015.1033454","volume":"50","author":"A Kjaer","year":"2015","unstructured":"Kjaer A, Knigge U. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors. Scand J Gastroenterol. 2015;50(6):740\u20137. https:\/\/doi.org\/10.3109\/00365521.2015.1033454","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"7941_CR13","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1097\/MNM.0000000000001416","volume":"42","author":"C Reilly","year":"2021","unstructured":"Reilly C, Gemmell AJ, McLaughlin IM, et al. Characterisation of 99mTc EDDA\/HYNIC-TOC (Tektrotyd) physiological and neuroendocrine tumour uptake using SPECT\/CT standardised uptake values: initial experience. Nucl Med Commun. 2021;42(8):935\u20139. . https:\/\/doi.org\/10.1097\/MNM.0000000000001416","journal-title":"Nucl Med Commun"},{"issue":"11","key":"7941_CR14","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.3390\/cancers14112725","volume":"14","author":"M Gherghe","year":"2022","unstructured":"Gherghe M, Laz\u0103r AM, Stanciu AE, et al. The New Radiolabeled Peptide 99mTcEDDA\/HYNIC-TOC: Is It a Feasible Choice for Diagnosing Gastroenteropancreatic NETs? Cancers (Basel). 2022;14(11):2725. https:\/\/doi.org\/10.3390\/cancers14112725","journal-title":"Cancers (Basel)"},{"issue":"12","key":"7941_CR15","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1097\/RLU.0000000000001877","volume":"42","author":"J Kunikowska","year":"2017","unstructured":"Kunikowska J, Lewington V, Krolicki L. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT\/SPECT\/CT Versus 68Ga-DOTATATE PET\/CT Upon Clinical Management. Clin Nucl Med. 2017;42(12):905\u201311. . https:\/\/doi.org\/10.1097\/RLU.0000000000001877","journal-title":"Clin Nucl Med"},{"issue":"2","key":"7941_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11912-017-0567-8","volume":"19","author":"M Cives","year":"2017","unstructured":"Cives M, Strosberg J. Radionuclide Therapy for Neuroendocrine Tumors. Curr Oncol Rep. 2017;19(2):9. https:\/\/doi.org\/10.1007\/s11912-017-0567-8","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"7941_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1053\/j.semnuclmed.2020.04.001","volume":"50","author":"JR Buscombe","year":"2020","unstructured":"Buscombe JR. Evidence Base for the Use of PRRT. Semin Nucl Med. 2020;50(5):399\u2013404. https:\/\/doi.org\/10.1053\/j.semnuclmed.2020.04.001","journal-title":"Semin Nucl Med"},{"key":"7941_CR18","doi-asserted-by":"publisher","unstructured":"Kolasi\u0144ska-\u0106wik\u0142a A, \u0141owczak A, Maciejkiewicz KM, et al. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective. Nucl Med Rev Cent East Eur. 2018;21(2). https:\/\/doi.org\/10.5603\/NMR.2018.0019","DOI":"10.5603\/NMR.2018.0019"},{"key":"7941_CR19","doi-asserted-by":"publisher","first-page":"861434","DOI":"10.3389\/fendo.2022.861434","volume":"13","author":"G Puliani","year":"2022","unstructured":"Puliani G, Chiefari A, Mormando M, et al. New Insights in PRRT: Lessons From 2021. Front Endocrinol (Lausanne). 2022;13:861434. . https:\/\/doi.org\/10.3389\/fendo.2022.861434","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7941_CR20","doi-asserted-by":"publisher","first-page":"941832","DOI":"10.3389\/fendo.2022.941832","volume":"13","author":"PE Harris","year":"2022","unstructured":"Harris PE, Zhernosekov K. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next? Front Endocrinol (Lausanne). 2022;13:941832. . https:\/\/doi.org\/10.3389\/fendo.2022.941832","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Suppl 1","key":"7941_CR21","first-page":"S83","volume":"46","author":"R Valkema","year":"2005","unstructured":"Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005;46(Suppl 1):S83\u201391.","journal-title":"J Nucl Med"},{"issue":"9","key":"7941_CR22","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00259-011-1835-8","volume":"38","author":"A Sowa-Staszczak","year":"2011","unstructured":"Sowa-Staszczak A, Pach D, Chrzan R, et al. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging. 2011;38(9):1669\u201374. https:\/\/doi.org\/10.1007\/s00259-011-1835-8","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"7941_CR23","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1007\/s00259-011-1833-x","volume":"38","author":"J Kunikowska","year":"2011","unstructured":"Kunikowska J, Kr\u00f3licki L, Hubalewska-Dydejczyk A, et al. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y\/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38(10):1788\u201397. https:\/\/doi.org\/10.1007\/s00259-011-1833-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7941_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","volume":"42","author":"L Bodei","year":"2015","unstructured":"Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42(1):5\u201319. https:\/\/doi.org\/10.1007\/s00259-014-2893-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"7941_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00259-013-2578-5","volume":"41","author":"E Seregni","year":"2014","unstructured":"Seregni E, Maccauro M, Chiesa C, et al. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Eur J Nucl Med Mol Imaging. 2014;41(2):223\u201330. https:\/\/doi.org\/10.1007\/s00259-013-2578-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"7941_CR26","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","volume":"41","author":"S Ezziddin","year":"2014","unstructured":"Ezziddin S, Khalaf F, Vanezi M, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41(5):925\u201333. https:\/\/doi.org\/10.1007\/s00259-013-2677-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7941_CR27","doi-asserted-by":"publisher","first-page":"501","DOI":"10.7150\/thno.13702","volume":"6","author":"RP Baum","year":"2016","unstructured":"Baum RP, Kluge AW, Kulkarni H, et al. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study. Theranostics. 2016;6(4):501\u201310. https:\/\/doi.org\/10.7150\/thno.13702","journal-title":"Theranostics"},{"issue":"1","key":"7941_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11523-023-01022-z","volume":"19","author":"Y Shin","year":"2024","unstructured":"Shin Y, Moon BH, Ryoo BY, et al. Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea. Target Oncol. 2024;19(1):41\u20139. https:\/\/doi.org\/10.1007\/s11523-023-01022-z","journal-title":"Target Oncol"},{"issue":"2","key":"7941_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s12020-019-01894-0","volume":"66","author":"A Faggiano","year":"2019","unstructured":"Faggiano A, Di Maio S, Mocerino C, et al. Therapeutic sequences in patients with grade 1\u20132 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Endocrine. 2019;66(2):417\u201324. https:\/\/doi.org\/10.1007\/s12020-019-01894-0","journal-title":"Endocrine"},{"issue":"10","key":"7941_CR30","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/imj.14336","volume":"49","author":"E Lin","year":"2019","unstructured":"Lin E, Chen T, Little A, Holliday L, et al. Safety and outcomes of 177 Lu-DOTATATE for neuroendocrine tumours: experience in New South Wales, Australia. Intern Med J. 2019;49(10):1268\u201377. https:\/\/doi.org\/10.1111\/imj.14336","journal-title":"Intern Med J"},{"issue":"22","key":"7941_CR31","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.3390\/cancers15225466","volume":"15","author":"AD Durma","year":"2023","unstructured":"Durma AD, Saracyn M, Ko\u0142odziej M, et al. Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE-A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center. Cancers (Basel). 2023;15(22):5466. https:\/\/doi.org\/10.3390\/cancers15225466","journal-title":"Cancers (Basel)"},{"issue":"2","key":"7941_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427","journal-title":"N Engl J Med"},{"issue":"25","key":"7941_CR33","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","volume":"36","author":"J Strosberg","year":"2018","unstructured":"Strosberg J, Wolin E, Chasen B, et al. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018;36(25):2578\u201384.","journal-title":"J Clin Oncol"},{"issue":"10","key":"7941_CR34","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1007\/s00259-020-04709-x","volume":"47","author":"J Strosberg","year":"2020","unstructured":"Strosberg J, Kunz PL, Hendifar A, et al. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020;47(10):2372\u201382. https:\/\/doi.org\/10.1007\/s00259-020-04709-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7941_CR35","doi-asserted-by":"publisher","unstructured":"Strosberg JR, Caplin ME, Kunz PL et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1752\u20131763. doi: 10.1016\/S1470-2045(21)00572-6. Epub 2021 Nov 15. Erratum in: Lancet Oncol. 2022;23(2):e59. https:\/\/doi.org\/10.1016\/S1470-2045(22)00028-6","DOI":"10.1016\/S1470-2045(22)00028-6"},{"issue":"10446","key":"7941_CR36","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403(10446):2807\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(24)00701-3","journal-title":"Lancet"},{"issue":"3","key":"7941_CR37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.5603\/EP.a2022.0049","volume":"73","author":"B Kos-Kud\u0142a","year":"2022","unstructured":"Kos-Kud\u0142a B, Foltyn W, Malczewska A, et al. Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2022;73(3):387\u2013454. . https:\/\/doi.org\/10.5603\/EP.a2022.0049","journal-title":"Endokrynol Pol"},{"issue":"2","key":"7941_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.5603\/EP.2017.0015","volume":"68","author":"B Kos-Kud\u0142a","year":"2017","unstructured":"Kos-Kud\u0142a B, Blicharz-Dorniak J, Strzelczyk J, et al. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2017;68(2):79\u2013110. https:\/\/doi.org\/10.5603\/EP.2017.0015","journal-title":"Endokrynol Pol"},{"issue":"3","key":"7941_CR39","doi-asserted-by":"publisher","first-page":"549","DOI":"10.5603\/EP.a2022.0052","volume":"73","author":"T Bednarczuk","year":"2022","unstructured":"Bednarczuk T, Zemczak A, Bolanowski M, et al. Neuroendocrine neoplasms of the small intestine and the appendix - update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2022;73(3):549\u201383. https:\/\/doi.org\/10.5603\/EP.a2022.0052","journal-title":"Endokrynol Pol"},{"issue":"12","key":"7941_CR40","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1007\/s12325-025-03383-5","volume":"42","author":"S Tafuto","year":"2025","unstructured":"Tafuto S, Lastoria S, Panzuto F, et al. The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion. Adv Ther. 2025;42(12):5931\u201349. https:\/\/doi.org\/10.1007\/s12325-025-03383-5","journal-title":"Adv Ther"},{"issue":"1","key":"7941_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40618-024-02448-6","volume":"48","author":"F Panzuto","year":"2025","unstructured":"Panzuto F, Albertelli M, De Rimini ML, et al. Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM). J Endocrinol Invest. 2025;48(1):23\u201336. https:\/\/doi.org\/10.1007\/s40618-024-02448-6","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"7941_CR42","doi-asserted-by":"publisher","first-page":"e13423","DOI":"10.1111\/jne.13423","volume":"36","author":"A Lamarca","year":"2024","unstructured":"Lamarca A, Bartsch DK, Caplin M, et al. European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours. J Neuroendocrinol. 2024;36(9):e13423. https:\/\/doi.org\/10.1111\/jne.13423","journal-title":"J Neuroendocrinol"},{"issue":"5","key":"7941_CR43","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.dld.2020.02.011","volume":"52","author":"L de Mestier","year":"2020","unstructured":"de Mestier L, Lepage C, Baudin E, et al. Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis. 2020;52(5):473\u201392.","journal-title":"Dig Liver Dis"},{"issue":"12","key":"7941_CR44","doi-asserted-by":"publisher","first-page":"e13343","DOI":"10.1111\/jne.13343","volume":"35","author":"B Kos-Kud\u0142a","year":"2023","unstructured":"Kos-Kud\u0142a B, Casta\u00f1o JP, Denecke T, et al. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol. 2023;35(12):e13343. https:\/\/doi.org\/10.1111\/jne.13343","journal-title":"J Neuroendocrinol"},{"issue":"8","key":"7941_CR45","doi-asserted-by":"publisher","first-page":"e13318","DOI":"10.1111\/jne.13318","volume":"35","author":"J Hofland","year":"2023","unstructured":"Hofland J, Falconi M, Christ E, et al. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol. 2023;35(8):e13318. https:\/\/doi.org\/10.1111\/jne.13318","journal-title":"J Neuroendocrinol"},{"issue":"5","key":"7941_CR46","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","volume":"49","author":"M Weber","year":"2022","unstructured":"Weber M, Lam M, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49(5):1682\u201399. https:\/\/doi.org\/10.1007\/s00259-021-05600-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7941_CR47","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s00259-007-0372-y","volume":"34","author":"J Tennvall","year":"2007","unstructured":"Tennvall J, Fischer M, Bischof Delaloye A, et al. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging. 2007;34(4):616\u201322. https:\/\/doi.org\/10.1007\/s00259-007-0372-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"7941_CR48","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1007\/s002590100599","volume":"28","author":"M Cybulla","year":"2001","unstructured":"Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med. 2001;28(10):1552\u20134. https:\/\/doi.org\/10.1007\/s002590100599","journal-title":"Eur J Nucl Med"},{"issue":"9287","key":"7941_CR49","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/S0140-6736(01)06220-1","volume":"358","author":"EP Cohen","year":"2001","unstructured":"Cohen EP, Moulder JE, Robbins ME. Radiation nephropathy caused by yttrium 90. Lancet. 2001;358(9287):1102-3. https:\/\/doi.org\/10.1016\/S0140-6736(01)06220-1","journal-title":"Lancet"},{"issue":"11","key":"7941_CR50","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00259-002-0935-x","volume":"29","author":"A Otte","year":"2002","unstructured":"OtteA, Cybulla M, Weiner SM. 90Y-DOTATOC and nephrotoxicity. Eur J Nucl Med Mol Imaging. 2002;29(11):1543. https:\/\/doi.org\/10.1007\/s00259-002-0935-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7941_CR51","first-page":"13","volume":"64","author":"J Kunikowska","year":"2013","unstructured":"Kunikowska J, Kr\u00f3licki L, Sowa-Staszczak A, et al. Nephrotoxicity after PRRT - still a serious clinical problem? Renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATATE and 90Y\/177Lu-DOTATATE. Endokrynol Pol. 2013;64(1):13\u201320","journal-title":"Endokrynol Pol"},{"key":"7941_CR52","doi-asserted-by":"publisher","unstructured":"Bodei L, Cremonesi M, Ferrari M et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35(10):1847-56. https:\/\/doi.org\/10.1007\/s00259-008-0778-1. Epub 2008 Apr 22. Erratum in: Eur J Nucl Med Mol Imaging. 2008;35(10):1928","DOI":"10.1007\/s00259-008-0778-1"},{"issue":"5","key":"7941_CR53","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s12149-017-1163-6","volume":"31","author":"J Kunikowska","year":"2017","unstructured":"Kunikowska J, Pawlak D, B\u0105k MI, et al. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y\/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study. Ann Nucl Med. 2017;31(5):347\u201356. https:\/\/doi.org\/10.1007\/s12149-017-1163-6","journal-title":"Ann Nucl Med"},{"key":"7941_CR54","unstructured":"de Jong M, Breeman WA, Valkema R et al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46 Suppl 1:13S-7S."},{"key":"7941_CR55","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/978-3-642-27994-2_26","volume":"194","author":"J Kunikowska","year":"2013","unstructured":"Kunikowska J, Kr\u00f3licki L, Sowa-Staszczak A, et al. Polish experience in Peptide receptor radionuclide therapy. Recent Results Cancer Res. 2013;194:467\u201378. https:\/\/doi.org\/10.1007\/978-3-642-27994-2_26","journal-title":"Recent Results Cancer Res"},{"issue":"4","key":"7941_CR56","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s00259-020-04690-5","volume":"47","author":"J Kunikowska","year":"2020","unstructured":"Kunikowska J, Zemczak A, Ko\u0142odziej M, et al. Tandem peptide receptor radionuclide therapy using 90Y\/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. Eur J Nucl Med Mol Imaging. 2020;47(4):922\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7941_CR57","doi-asserted-by":"publisher","first-page":"6615511","DOI":"10.1155\/2021\/6615511","volume":"2021","author":"A Zemczak","year":"2021","unstructured":"Zemczak A, Gut P, Pawlak D, et al. The Safety and Efficacy of the Repeated PRRT with [90Y]Y\/[177Lu]Lu-DOTATATE in Patients with NET. Int J Endocrinol. 2021;2021:6615511. https:\/\/doi.org\/10.1155\/2021\/6615511","journal-title":"Int J Endocrinol"},{"issue":"9","key":"7941_CR58","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3390\/ph16091205","volume":"16","author":"AD Durma","year":"2023","unstructured":"Durma AD, Saracyn M, Ko\u0142odziej M, et al. Radioligand Therapy with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade. Pharmaceuticals (Basel). 2023;16(9):1205. https:\/\/doi.org\/10.3390\/ph16091205","journal-title":"Pharmaceuticals (Basel)"},{"issue":"16","key":"7941_CR59","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, van Eijck CHJ, Franssen GJH, Krenning EP, Kwekkeboom DJ. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res. 2017;23(16):4617\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2743","journal-title":"Clin Cancer Res"},{"key":"7941_CR60","unstructured":"NETTER3. https:\/\/clinicaltrials.gov\/study\/NCT06784752 (access 10 JAN 2026)."},{"issue":"1","key":"7941_CR61","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022;33(1):115\u201354. . https:\/\/doi.org\/10.1007\/s12022-022-09708-2","journal-title":"Endocr Pathol"},{"key":"7941_CR62","unstructured":"Hofland J, de Herder WW. Gastrointestinal Neuroendocrine Tumors and the Carcinoid Syndrome. [Updated 2023 Aug 25]. In: Feingold KR, Adler RA, Ahmed SF, et al., editors.Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Table 1. [TNM staging of gastrointestinal neuroendocrine\u2026 Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279162\/table\/carcinoid-tumors.T.tnm_staging_of_gastro\/."},{"key":"7941_CR63","doi-asserted-by":"publisher","first-page":"62","DOI":"10.5603\/nmr.102682","volume":"27","author":"I Cieszykowska","year":"2024","unstructured":"Cieszykowska I, Rybak P, Janiak T, et al. Quantitative assessment of radioactivity losses in the administration of therapeutic doses of [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE. Nucl Med Rev Cent East Eur. 2024;27:62\u201371. https:\/\/doi.org\/10.5603\/nmr.102682","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"7941_CR64","doi-asserted-by":"publisher","unstructured":"KidneyDisease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","DOI":"10.1016\/j.kint.2023.10.018"},{"issue":"17","key":"7941_CR65","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","volume":"29","author":"A Imhof","year":"2011","unstructured":"Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416\u201323.","journal-title":"J Clin Oncol"},{"issue":"11","key":"7941_CR66","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s002590050476","volume":"26","author":"A Otte","year":"1999","unstructured":"Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26(11):1439\u201347.","journal-title":"Eur J Nucl Med"},{"issue":"1","key":"7941_CR67","doi-asserted-by":"publisher","first-page":"101295","DOI":"10.1016\/j.tranon.2021.101295","volume":"15","author":"AS Parihar","year":"2022","unstructured":"Parihar AS, Chopra S, Prasad V. Nephrotoxicity after radionuclide therapies. Transl Oncol. 2022;15(1):101295. https:\/\/doi.org\/10.1016\/j.tranon.2021.101295","journal-title":"Transl Oncol"},{"key":"7941_CR68","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1479-5876-11-17","volume":"11","author":"N Marincek","year":"2013","unstructured":"Marincek N, J\u00f6rg AC, Brunner P, et al. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. J Transl Med. 2013;11:17. https:\/\/doi.org\/10.1186\/1479-5876-11-17","journal-title":"J Transl Med"},{"issue":"3","key":"7941_CR69","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000324096","volume":"93","author":"AK Pfeifer","year":"2011","unstructured":"Pfeifer AK, Gregersen T, Gr\u00f8nb\u00e6k H, et al. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort. Treat Switz Neuroendocrinol. 2011;93(3):189\u201396.","journal-title":"Treat Switz Neuroendocrinol"},{"issue":"1","key":"7941_CR70","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s00259-025-07418-5","volume":"53","author":"AD Durma","year":"2025","unstructured":"Durma AD, Saracyn M, J\u00f3\u017awik-Plebanek K, et al. Complications and outcomes of radioligand therapy in patients with neuroendocrine neoplasms depending on the baseline glomerular filtration rate. Eur J Nucl Med Mol Imaging. 2025;53(1):320\u20139. https:\/\/doi.org\/10.1007\/s00259-025-07418-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"7941_CR71","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","volume":"43","author":"H Bergsma","year":"2016","unstructured":"Bergsma H, Konijnenberg MW, van der Zwan WA, Kam BL, Teunissen JJ, Kooij PP, Mauff KA, Krenning EP, Kwekkeboom DJ. Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging. 2016;43(10):1802\u201311. https:\/\/doi.org\/10.1007\/s00259-016-3382-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7941_CR72","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13550-025-01305-8","volume":"15","author":"FL Herr","year":"2025","unstructured":"Herr FL, Dascalescu C, Fusch V, Smith C, Ebner R, Zacherl MJ, Eckenweber F, Klimek K, Auernhammer CJ, Spitzweg C, Ricke J, Heimer MM, Cyran CC, Werner RA, Sheikh GT. Predictors of renal function decline in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy. EJNMMI Res. 2025;15(1):110. https:\/\/doi.org\/10.1186\/s13550-025-01305-8","journal-title":"EJNMMI Res"},{"key":"7941_CR73","doi-asserted-by":"publisher","first-page":"1716247","DOI":"10.3389\/fendo.2025.1716247","volume":"16","author":"M Kolodziej","year":"2025","unstructured":"Kolodziej M, Opalinska M, Mikolajczak R, et al. Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial. Front Endocrinol (Lausanne). 2025;16:1716247. https:\/\/doi.org\/10.3389\/fendo.2025.1716247","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"7941_CR74","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1016\/j.ekir.2021.10.006","volume":"6","author":"AC van der Burgh","year":"2021","unstructured":"van der Burgh AC, Rizopoulos D, Ikram MA, Hoorn EJ, Chaker L. Determinants of the Evolution of Kidney Function With Age. Kidney Int Rep. 2021;6(12):3054\u201363. https:\/\/doi.org\/10.1016\/j.ekir.2021.10.006","journal-title":"Kidney Int Rep"},{"issue":"11","key":"7941_CR75","doi-asserted-by":"publisher","first-page":"e089783","DOI":"10.1136\/bmjopen-2024-089783","volume":"14","author":"M Guppy","year":"2024","unstructured":"Guppy M, Thomas ET, Glasziou P, Clark J, Jones M, O\u2019Hara DV, Doust J. Rate of decline in kidney function with age: a systematic review. BMJ Open. 2024;14(11):e089783. https:\/\/doi.org\/10.1136\/bmjopen-2024-089783","journal-title":"BMJ Open"},{"issue":"3","key":"7941_CR76","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s12029-024-01065-z","volume":"55","author":"US Grewal","year":"2024","unstructured":"Grewal US, Loeffler BT, Paschke A, et al. Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors: A NET Center of Excellence Experience. J Gastrointest Cancer. 2024;55(3):1165\u201370. https:\/\/doi.org\/10.1007\/s12029-024-01065-z","journal-title":"J Gastrointest Cancer"},{"issue":"10","key":"7941_CR77","doi-asserted-by":"publisher","first-page":"e47506","DOI":"10.7759\/cureus.47506","volume":"15","author":"MM Silva","year":"2023","unstructured":"Silva MM, Canha M, Salazar D, et al. Efficacy, Toxicity, and Prognostic Factors of Re-treatment With [177Lu]Lu-DOTA-TATE in Patients With Progressing Neuroendocrine Tumors: The Experience of a Single Center. Cureus. 2023;15(10):e47506. https:\/\/doi.org\/10.7759\/cureus.47506","journal-title":"Cureus"},{"key":"7941_CR78","doi-asserted-by":"publisher","unstructured":"Durma AD, Saracyn M, Ko\u0142odziej M et al. Re-treatment with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE of patients with progressive neuroendocrine neoplasm. Nucl Med Rev Cent East Eur. 2023;26(0):143\u2013152. https:\/\/doi.org\/10.5603\/nmr.96672","DOI":"10.5603\/nmr.96672"},{"issue":"6","key":"7941_CR79","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/oncolo\/oyab072","volume":"27","author":"H Duan","year":"2022","unstructured":"Duan H, Ferri V, Fisher GA, Shaheen S, Davidzon GA, Iagaru A, Mari Aparici C. Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up. Oncologist. 2022;27(6):447\u201352. https:\/\/doi.org\/10.1093\/oncolo\/oyab072","journal-title":"Oncologist"},{"issue":"1","key":"7941_CR80","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5603\/NMR.a2022.0016","volume":"25","author":"B Bober","year":"2022","unstructured":"Bober B, Saracyn M, Lubas A, Kolodziej M, Brodowska-Kania D, Kapusta W, Kaminski G. Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm. Nucl Med Rev Cent East Eur. 2022;25(1):54\u201361. https:\/\/doi.org\/10.5603\/NMR.a2022.0016","journal-title":"Nucl Med Rev Cent East Eur"},{"issue":"6","key":"7941_CR81","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2967\/jnumed.124.268880","volume":"66","author":"E Deshayes","year":"2025","unstructured":"Deshayes E, Karfis I, Santoro L, et al. Patient-Specific Dosimetry-Driven PRRT: Time to Move Forward! J Nucl Med. 2025;66(6):983. . https:\/\/doi.org\/10.2967\/jnumed.124.268880","journal-title":"J Nucl Med"},{"issue":"1","key":"7941_CR82","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13550-024-01163-w","volume":"14","author":"R Danieli","year":"2024","unstructured":"Danieli R, Mileva M, Marin G, et al. Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study. EJNMMI Res. 2024;14(1):110. https:\/\/doi.org\/10.1186\/s13550-024-01163-w","journal-title":"EJNMMI Res"},{"issue":"9","key":"7941_CR83","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1007\/s00259-017-3678-4","volume":"44","author":"A Sundl\u00f6v","year":"2017","unstructured":"Sundl\u00f6v A, Sj\u00f6green-Gleisner K, Svensson J, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44(9):1480\u20139. https:\/\/doi.org\/10.1007\/s00259-017-3678-4","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07941-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07941-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07941-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:10:10Z","timestamp":1785521410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07941-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":83,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7941"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07941-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":1,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Medical University of Warsaw (consent no KB\/16\/2005 and KB\/21\/K\/2011).","order":2,"name":"Ethics","label":"Institutional Review Board Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}